FDA approves Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers, enhancing treatment options.

Back pain is more common in women than you think. An AIIMS orthopaedic surgeon shares 3 essential tests that can help detect the root cause early.

Heard These Health Myths Before? It's Time Women Stopped Believing Them Women's health has long been surrounded by myths,...

The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like ...

The global Medical Device Technology Market is on an accelerated growth path, estimated at USD 575.6 billion in 2025 and ...

Dr. Carrie Jose, in her latest Health and Wellness column, says that 60 is the new 40, and why longevity is the health trend ...

Earlier this month, the FDA approved Bildyos and Bilprevda (denosumab-nxxp), 2 additional denosumab biosimilars for Prolia ...

The Food and Drug Administration (FDA) has approved Bosaya ™ (denosumab-kyqq) and Aukelso ™ (denosumab-kyqq), biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively.

Here's the best time to take calcium to reap all the potential benefits, plus other important factors and tips nutrition ...

Infertility was among the fertility history factors that were associated with increased risk for osteoporosis among postmenopausal women.

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now . Organon & Co. stands eleventh among ...